Tag : INTRACAMERAL IMPLANT

  • NEWS AND PERSPECTIVE
    Novel micro-invasive injectable treatment for glaucoma receives FDA approval

    The travoprost intracameral implant has demonstrated non-inferiority towards topical timolol ophthalmic solution in reducing intraocular pressure (IOP) of patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) in 2 phase 3 randomized controlled trial, which led to its approval from the United States (US) Food and Drug Administration (FDA) in December 2023, offering an alternate treatment option for patients with OAG or OHT.